Smith & Nephew plc ADR Stock
Pros and Cons of Smith & Nephew plc ADR in the next few years
Pros
?
C******** o* t** e**********
?
G***** c******* t* c**********
?
S********** s********
Cons
?
M***** P*******
?
W********* I********* f** t** n*** y****
?
B****
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Smith & Nephew plc ADR vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Smith & Nephew plc ADR | - | -0.694% | 2.143% | 17.213% | 2.143% | 10.853% | -19.209% |
| Smith & Nephew plc | -1.580% | -3.643% | -0.708% | 12.882% | -1.372% | 8.682% | -21.014% |
| Dexcom Inc. | -2.670% | -3.928% | 3.635% | -28.806% | 1.971% | -40.369% | -20.692% |
| Thermo Fisher Scientific Inc. | -2.320% | -0.625% | 8.192% | -3.728% | 6.091% | -2.781% | 25.296% |
Comments
Smith & Nephew SNATS (NYSE:SNN) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew SNATS (NYSE:SNN) had its "outperform" rating reaffirmed by analysts at Royal Bank Of Canada.
Show more
Ratings data for SNN provided by MarketBeat
Smith & Nephew plc (NYSE: SNN) is now covered by analysts at Deutsche Bank Aktiengesellschaft. They set a "buy" rating on the stock.
Show more
Ratings data for SNN provided by MarketBeat
